NL300917I2 - Midostaurine, desgewenst in de vorm van een zout - Google Patents

Midostaurine, desgewenst in de vorm van een zout Download PDF

Info

Publication number
NL300917I2
NL300917I2 NL300917C NL300917C NL300917I2 NL 300917 I2 NL300917 I2 NL 300917I2 NL 300917 C NL300917 C NL 300917C NL 300917 C NL300917 C NL 300917C NL 300917 I2 NL300917 I2 NL 300917I2
Authority
NL
Netherlands
Prior art keywords
warm
treatment
midostaurine
salt
optionally
Prior art date
Application number
NL300917C
Other languages
English (en)
Other versions
NL300917I1 (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300917(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL300917I1 publication Critical patent/NL300917I1/nl
Publication of NL300917I2 publication Critical patent/NL300917I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL300917C 2003-06-18 2017-12-07 Midostaurine, desgewenst in de vorm van een zout NL300917I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
EP04740016A EP1638574B1 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (2)

Publication Number Publication Date
NL300917I1 NL300917I1 (nl) 2017-12-12
NL300917I2 true NL300917I2 (nl) 2018-01-09

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300917C NL300917I2 (nl) 2003-06-18 2017-12-07 Midostaurine, desgewenst in de vorm van een zout

Country Status (24)

Country Link
US (2) US8575146B2 (nl)
EP (1) EP1638574B1 (nl)
JP (2) JP5057780B2 (nl)
CN (2) CN100457111C (nl)
AT (1) ATE464052T1 (nl)
AU (1) AU2004248909B2 (nl)
BE (1) BE2017C067I2 (nl)
BR (1) BRPI0411563B8 (nl)
CA (2) CA2785950A1 (nl)
CY (2) CY1110179T1 (nl)
DE (1) DE602004026578D1 (nl)
DK (1) DK1638574T3 (nl)
ES (1) ES2344700T3 (nl)
FR (1) FR17C1063I2 (nl)
HK (1) HK1095519A1 (nl)
HU (1) HUS000503I2 (nl)
LU (1) LUC00055I9 (nl)
MX (1) MXPA05013722A (nl)
NL (1) NL300917I2 (nl)
PL (1) PL1638574T3 (nl)
PT (1) PT1638574E (nl)
SI (1) SI1638574T1 (nl)
TW (1) TWI324604B (nl)
WO (1) WO2004112794A2 (nl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
DE602004020654D1 (de) 2003-11-18 2009-05-28 Novartis Ag Hemmer der mutanten form von kit
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
AU2005274852B2 (en) * 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CA2606716C (en) * 2005-05-02 2013-07-23 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
AU2006271652B2 (en) * 2005-07-20 2010-04-29 Peter Valent Compositions for treatment of systemic mastocytosis
RU2443421C2 (ru) * 2005-11-14 2012-02-27 Университэт Цюрих Производные стауроспорина для применения при лечении альвеолярной рабдомиосаркомы
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
WO2012064981A2 (en) 2010-11-10 2012-05-18 National Jewish Health Methods to test allergic conditions
BR112021008516A2 (pt) 2018-11-01 2021-09-14 Syros Pharmaceuticals, Inc. Inibidores de quinase 7 dependente de ciclina (cdk 7)
US11325978B2 (en) * 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
EP0518468B1 (en) * 1991-05-09 1999-06-30 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US6184217B1 (en) * 1996-06-25 2001-02-06 Cephalon, Inc. Use of K-252a derivative
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
MXPA03005139A (es) * 2000-12-08 2004-01-29 Ortho Mcneil Pharm Inc Compuestos macroheterociclicos utiles como inhibidores de cinasa.
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
JPWO2004091663A1 (ja) 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
DE602004020654D1 (de) 2003-11-18 2009-05-28 Novartis Ag Hemmer der mutanten form von kit

Also Published As

Publication number Publication date
EP1638574B1 (en) 2010-04-14
WO2004112794A3 (en) 2005-06-16
LUC00055I9 (nl) 2022-11-09
US8575146B2 (en) 2013-11-05
CY2017048I2 (el) 2018-09-05
LUC00055I2 (nl) 2018-02-21
LUC00055I1 (nl) 2017-12-14
NL300917I1 (nl) 2017-12-12
CN100457111C (zh) 2009-02-04
SI1638574T1 (sl) 2010-08-31
BE2017C067I2 (nl) 2023-08-09
JP2012144572A (ja) 2012-08-02
CA2527703A1 (en) 2004-12-29
JP2006527727A (ja) 2006-12-07
AU2004248909A1 (en) 2004-12-29
ATE464052T1 (de) 2010-04-15
CA2527703C (en) 2012-10-23
TWI324604B (en) 2010-05-11
ES2344700T3 (es) 2010-09-03
JP5057780B2 (ja) 2012-10-24
DE602004026578D1 (de) 2010-05-27
WO2004112794A2 (en) 2004-12-29
EP1638574A2 (en) 2006-03-29
CN101164539A (zh) 2008-04-23
FR17C1063I1 (nl) 2018-02-16
BRPI0411563B1 (pt) 2019-09-24
CN1805749A (zh) 2006-07-19
US20070299049A1 (en) 2007-12-27
HUS000503I2 (hu) 2021-03-29
PT1638574E (pt) 2010-07-14
DK1638574T3 (da) 2010-08-02
US20130289018A1 (en) 2013-10-31
CY1110179T1 (el) 2015-01-14
BRPI0411563B8 (pt) 2021-05-25
AU2004248909B2 (en) 2008-05-08
CA2785950A1 (en) 2004-12-29
TW200512213A (en) 2005-04-01
BRPI0411563A (pt) 2006-08-01
PL1638574T3 (pl) 2010-09-30
CY2017048I1 (el) 2018-09-05
MXPA05013722A (es) 2006-03-08
HUS1700053I1 (hu) 2018-01-29
HK1095519A1 (en) 2007-05-11
FR17C1063I2 (fr) 2019-05-03

Similar Documents

Publication Publication Date Title
NL300917I2 (nl) Midostaurine, desgewenst in de vorm van een zout
DK1611088T3 (da) Hydroxymater som terapeutiske midler
ATE520668T1 (de) Sigmarezeptor-inhibitoren
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
ATE517882T1 (de) Chinolinderivate
MY148246A (en) Bicyclic amides as kinase inhibitors
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA200971053A1 (ru) Способы лечения кожных язв
EA201390353A1 (ru) Производное пиразолохинолина
GB2427405A (en) Novel hydroxamates as therapeutic agents
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BR112012004851B8 (pt) uso de um derivado de tiazol
EA201101579A1 (ru) Имидазо[1,2-а]пиридин-2-ил-фенил производные для лечения рака
MX2008011020A (es) Compuestos de receptor sigma.
WO2006014703A3 (en) Homopiperdinine derivatives as nk-1 antagonists
EA200970293A1 (ru) Новые производные 5-тиоксилопиранозы
EA200701086A1 (ru) Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли